Class Action Lawsuit Filed Against Cytokinetics, Incorporated

Strategic Insights -

Shareholders who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) during the period from December 27, 2023 to May 6, 2025 are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment in a class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy ("REMS") that could delay the regulatory process.

Key Takeaways:

  • The class action lawsuit alleges that Cytokinetics, Incorporated made materially false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten.
  • The lawsuit claims that defendants represented that the Company expected approval from the FDA in the second half of 2025, based on a PDUFA date of September 26, 2025.
  • The defendants allegedly failed to disclose material risks related to the Company's failure to submit a REMS that could delay the regulatory process.
  • Shareholders who purchased shares of CYTK during the period from December 27, 2023 to May 6, 2025 are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm that seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock.
  • The lawn firm has a mission to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.

Statistics:

  • Class period: December 27, 2023 to May 6, 2025
  • Deadine to seek to be a lead plaintiff: November 17, 2025
  • Contact information: dg@securitiesclasslaw.com or (646) 453-8903

Sources:

  • "New York, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK)."
  • "The Gross Law Firm is a nationally recognized class action law firm..."
  • "View original content to download multimedia: SOURCE The Gross Law Firm"